Type I interferons in anticancer immunity

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148

Virus interference. I. the interferon

Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451

The Three Es of Cancer Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic

Parsels, L. A., Zhang, Q., Karnak, D. M., Parsels, J. D., Lam, K., Willers, H., Green, M. D., Rehemtulla, A., Lawrence, T. S., & Morgan, M. A. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.07.1708 · Cited by 11

An integrin axis induces IFN-β production in plasmacytoid dendritic cells

Simoes, D. C. M., Paschalidis, N., Kourepini, E., & Panoutsakopoulou, V. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202102055 · Cited by 12

Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities

Rezaei, M., Danilova, N. D., Soltani, M., Savvateeva, L. V., Tarasov, V. V., Ganjalıkhani-Hakemi, M., Bazhin, A. V., & Zamyatnin, A. A. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220214103533 · Cited by 11

Glyco-Nanoadjuvants: Impact of Linker Length for Conjugating a Synthetic Small-Molecule TLR7 Ligand to Glyco-Nanoparticles on Immunostimulatory Effects

Shinchi, H., Komaki, F., Yuki, M., Ohara, H., Hayakawa, N., Wakao, M., Cottam, H. B., Hayashi, T., Carson, D. A., Moroishi, T., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00108 · Cited by 11

Different Roles of Dendritic Cells for Chronic Rhinosinusitis Treatment According to Phenotype

Tai, J., Kwak, J., Han, M. S., & Kim, T. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23148032 · Cited by 11

Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP‐1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer

Luo, B., Zhang, S., Tan, D., Yu, X., Lin, J., & Wang, M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8965903 · Cited by 11

Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses

D’Angelo, A., Kilili, H., Chapman, R., Generali, D., Tinhofer, I., Luminari, S., Donati, B., Ciarrocchi, A., Giannini, R., Moretto, R., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280364 · Cited by 11

Harnessing dendritic cell diversity in cancer immunotherapy

Park, H., Ashayeripanah, M., & Chopin, M. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102341 · Cited by 11

Metabolic Endotoxemia-Activated Macrophages Promote Pancreatic β Cell Death via IFNβ-Xaf1 Pathway

Tsuruta, M., Iwashita, M., Shinjo, T., Matsunaga, H., Yamashita, A., & Nishimura, F. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-121467 · Cited by 11

Anticancer Mechanisms in Two Murine Bone Marrow–Derived Dendritic Cell Subsets Activated with TLR4 Agonists

Bagaev, A., Av, P., Nelson, E. L., Agadjanyan, M. G., Ghochikyan, A., & Ataullakhanov, R. I. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701126 · Cited by 11

Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha

Young, P. A., Yamada, R. E., Trinh, K. R., Vasuthasawat, A., Oliveira, S. N. D., Yamada, D. H., Morrison, S. L., & Timmerman, J. M. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0030 · Cited by 11

Distinct evolution of toll-like receptor signaling pathway genes in cetaceans

Tian, R., Seim, I., Zhang, Z., Yang, Y., Ren, W., Xu, S., & Yang, G. (2019) · Genes & Genomics · doi:10.1007/s13258-019-00861-3 · Cited by 11

Dual requirement for STAT signaling in dendritic cell immunobiology

Donninelli, G., Sanseverino, I., Purificato, C., Gessani, S., & Gauzzi, M. C. (2017) · Immunobiology · doi:10.1016/j.imbio.2017.10.049 · Cited by 11

Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity

Xie, Q., Du, Y., Ghosh, S., Rajendran, S., Cohen-Gadol, A. A., Baizabal, J.-M., Nephew, K. P., Han, L., & Shen, J. (2025) · NPJ Precision Oncology · doi:10.1038/s41698-025-00829-5 · Cited by 10

NLRC5 potentiates anti-tumor CD8+ T cells responses by activating interferon-β in endometrial cancer

Zhang, J., Guo, B., Chen, J.-H., Liu, X.-J., Zhang, J., Zhu, H., Wang, W., Tang, Z., Wei, B., Cao, Y., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101742 · Cited by 10

Enhanced Tumor Immunotherapy by Triple Amplification Effects of Nanomedicine on the STING Signaling Pathway in Dendritic Cells

Wang, X., Yan, Y., Guo, X. N., Lu, A., Jiang, L., Zhu, Y., Shi, Y., Liu, X., & Wang, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202403143 · Cited by 13

Photothermal therapy combined with a STING agonist induces pyroptosis, and gasdermin D could be a new biomarker for guiding the treatment of pancreatic cancer

Hu, Y., Qi, E., Yun, C., Li, X., Liu, F., Cheng, Z., Guan, N., Wang, Q., Zhao, H., Xiao, W., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06247-2 · Cited by 10

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition

Guo, Y., Li, Z., Parsels, L. A., Wang, Z., Parsels, J. D., Dalvi, A., The, S., Hu, N., Valvo, V. M., Doherty, R. E., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf097 · Cited by 10

Comparative analyses for plant virus-based cancer immunotherapy drug development

Omole, A. O., Newton, H. S., Cedrone, E., Nematpour, K., Xie, S., Zhao, Y., Tran, B., Dobrovolskaia, M. A., & Steinmetz, N. F. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100095 · Cited by 10

NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors

Gao, Y., Zuo, L., Zheng, Y., Sun, K., Gao, Y., Xu, X., Li, Z., & Zuo, D. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02045-2 · Cited by 12

Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation

Inoue, H. (2026) · Viruses · doi:10.3390/v18040461 · Cited by 10

Adaptive resistance in cancer immunotherapy

Yang, K. E., Yang, C., Xiong, K., Hao, J., & Ye, L. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01424-9 · Cited by 11

Primary and metastatic breast tumors cross-talk to influence immunotherapy responses

Oliver, A. J., Keam, S. P., von Scheidt, B., Zanker, D. J., Harrison, A. J., Tantalo, D. G. M., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1802979 · Cited by 10

Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers

Aiba, T., Hattori, C., Sugisaka, J., Shimizu, H., Ono, H., Domeki, Y., Saito, R., Kawana, S., Kawashima, Y., Terayama, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260500 · Cited by 10

Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy

Schunke, J., Mailänder, V., Landfester, K., & Fichter, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512174 · Cited by 11

Monitoring Melanoma Responses to STING Agonism and Focused Ultrasound Thermal Ablation Using Microneedles and Ultrasensitive Single Molecule Arrays

Dahis, D., Dion, M. Z., Cryer, A. M., Dosta, P., Gilboa, T., Alonso, M., Lewandowski, M., Puigmal, N., Taboada, G. M., Azhari, H., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202301659 · Cited by 10

A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

Lint, S. V., Parys, A. V., Eeckhout, B. V. D., Vandamme, N., Plaisance, S., Verhee, A., Catteeuw, D., Rogge, E., Geest, J. D., Vanderroost, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01908-6 · Cited by 10

B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/β response in bone marrow-derived mesenchymal stroma

Smeets, M. W. E., Steeghs, E. M. P., Orsel, J., Stalpers, F., Vermeeren, M. M. P., Veltman, C. H. J., Slenders, L., Nierkens, S., van de Ven, C., & den Boer, M. L. (2024) · Haematologica · doi:10.3324/haematol.2023.283494 · Cited by 10

Type I interferon signaling regulates myeloid and T cell crosstalk in the glioblastoma tumor microenvironment

Lim, J., La, J., Kim, H. C., Kang, I., Kang, B. H., Ku, K. B., Kim, Y., Kwon, M. S., & Lee, H. K. (2024) · iScience · doi:10.1016/j.isci.2024.110810 · Cited by 10

Cytotoxic effects induced by interferon-ω gene lipofection through ROS generation and mitochondrial membrane potential disruption in feline mammary carcinoma cells

Villaverde, M. S., Targovnik, A. M., Miranda, M. V., Finocchiaro, L. M. E., & Glikin, G. C. (2016) · Cytokine · doi:10.1016/j.cyto.2016.05.018 · Cited by 10

Innate sensing of cancer's non-immunologic hallmarks

Seelige, R., Searles, S. C., & Bui, J. D. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.09.005 · Cited by 10

Signal‐transducing innate receptors in tumor immunity

Hangai, S., Kimura, Y., Taniguchi, T., & Yanai, H. (2021) · Cancer Science · doi:10.1111/cas.14848 · Cited by 12

Targeting cytokinesis bridge proteins to kill high-CIN type tumors

Xie, B., Liang, X., Yue, W., Ma, J., Li, X., Zhang, N., Wang, P., Liu, C., Shi, X., Qiao, J., et al. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.08.015 · Cited by 10

Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer

Vergato, C., Doshi, K. A., Roblyer, D. M., & Waxman, D. J. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0148 · Cited by 10

Virus‐Like Particle‐Induced cGAS‐STING Activation and AIM2 Inflammasome‐Mediated Pyroptosis for Robust Cancer Immunotherapy

Xu, X., Fan, H., Yang, Y., Yao, S., Yu, W., Guo, Z., & Tan, W. (2023) · Angewandte Chemie · doi:10.1002/ange.202303010 · Cited by 10

Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix

Kuwashiro, T., Iwane, S., Xia, J., Matsuhashi, S., Eguchi, Y., Anzai, K., Fujimoto, K., Mizuta, T., Sakamoto, N., Ikeda, M., et al. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3693 · Cited by 10

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models

Kaistha, B. P., Kar, G., Dannhorn, A., Watkins, A., Opoku‐Ansah, G., Ilieva, K. M., Mullins, S., Anderton, J., Galvani, E., Garçon, F., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2296048 · Cited by 10

Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate Cancer

Alnukhali, M., Altabbakh, O., Farooqı, A. A., Pollack, A. S., Daunert, S., Deo, S. K., & Tao, W. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673273303231208071403 · Cited by 9

Revitalizing antitumor immunity: Leveraging nucleic acid sensors as therapeutic targets

Liu, D., He, W., & Yang, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216729 · Cited by 9

A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer

Zuo, X., Cheng, Q., Wang, Z., Liu, J., Lu, W., Wu, G., Zhu, S., Liu, X., Lv, T., & Song, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112478 · Cited by 9

Intratumoral NKT cell accumulation promotes antitumor immunity in pancreatic cancer

Li, J., Moresco, P., & Fearon, D. T. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403917121 · Cited by 9

Engineering interferons for cancer immunotherapy

Lim, J., & Lee, H. K. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117426 · Cited by 9

Design, Synthesis, and Pharmacological Evaluation of Quinazoline and Quinoline Derivatives as Potent ENPP1 Inhibitors for Cancer Immunotherapy

He, J., Ma, X., Sun, J., Chen, M., Xu, L., Song, Z., Ding, C., Meng, L., & Zhang, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03207 · Cited by 9

Live biotherapeutic enterococcus lactis MNC-168 promotes the efficacy of immune checkpoint blockade in cancer therapy by activating STING pathway via bacterial membrane vesicles

Xian, Y., Chen, Z., Lan, Z., Zhang, C., Sun, H., Liu, Z., Kong, P., Liang, Y., Zhao, Y., Liu, S. M., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2557978 · Cited by 10

Polypeptide sono-adjuvant for ultrasound-activatable regulation of innate immunity and cancer vaccination therapy

Chen, F., Zhang, H., Li, S., Ren, S., Huang, L., Guo, Y. L., Lai, Y., Cai, Z., Liu, X., Xu, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66976-2 · Cited by 9

Striking the right balance with type I interferon signalling in cancer

Chadwick, T. B., So, J., Hertzog, P. J., Haynes, N. M., & Parker, B. S. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00915-1 · Cited by 14

Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results

Gonçalvès, A., Mezni, E., & Bertucci, F. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000680 · Cited by 9

Transcriptome and genome evolution during HER2-amplified breast neoplasia

Lu, P., Foley, J. W., Zhu, C., McNamara, K. L., Sirinukunwattana, K., Vennam, S., Varma, S., Fehri, H., Srivastava, A., Zhu, S., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01451-6 · Cited by 9

Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy

Lewicky, J. D., Martel, A. L., Fraleigh, N. L., Picard, E., Mousavifar, L., Nakamura, A., Díaz‐Mitoma, F., Roy, R., & Le, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122710 · Cited by 9

Transcriptomic Analysis of Mycobacterial Infected Macrophages Reveals a High MOI Specific Type I IFN Signaling

Ding, Y., Bei, C., Xue, Q., Niu, L., Tong, J., Chen, Y., Takiff, H. E., Gao, Q., & Yan, B. (2023) · Infection and Immunity · doi:10.1128/iai.00155-23 · Cited by 9

Comprehensive analyses for the coagulation and macrophage-related genes to reveal their joint roles in the prognosis and immunotherapy of lung adenocarcinoma patients

Li, Z., Yin, Z., Luan, Z., Zhang, C., Wang, Y., Zhang, K., Chen, F., Yang, Z., & Tian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1273422 · Cited by 9

Lactate inhibits interferon-α response in ovarian cancer by inducing STAT1 ubiquitin degradation

Dong, X., Lin, C., Xu, L., Zeng, C., Zeng, L., Wei, Z., Zeng, L., & Yao, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111099 · Cited by 9

Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management

Gorenšek, R., Kresnik, M., Takač, I., Rojko, T., & Sobočan, M. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s399157 · Cited by 9

Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy

Chai, F., Li, P., Liu, X., Zhou, Z., & Ren, H. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad070 · Cited by 9

Integrating bulk and single-cell sequencing data to construct a Scissor+ dendritic cells prognostic model for predicting prognosis and immune responses in ESCC

Cheng, M., Xiong, J., Liu, Q., Zhang, C., Li, K., Wang, X., & Chen, S. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03683-9 · Cited by 10

“Toll-free” pathways for production of type I interferons

Wang, L., & Ning, S. (2017) · AIMS Allergy and Immunology · doi:10.3934/allergy.2017.3.143 · Cited by 9

Novel chemical compound SINCRO with dual function in STING ‐type I interferon and tumor cell death pathways

Kimura, Y., Negishi, H., Matsuda, A., Endo, N., Hangai, S., Inoue, A., Nishio, J., Taniguchi, T., & Yanai, H. (2018) · Cancer Science · doi:10.1111/cas.13726 · Cited by 9

Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas

Verver, D., Poirier-Colame, V., Tomasic, G., Cherif-Rebai, K., Grünhagen, D. J., Verhoef, C. K., Suciu, S., Robert, C., Zitvogel, L., & Eggermont, A. M. M. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1660121 · Cited by 9

Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity

Lohmann, B., Silginer, M., Picard, D. J., Schneider, H., Remke, M., Roth, P., Reifenberger, G., & Weller, M. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa043 · Cited by 9

Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses

Liu, P., Zhao, L., Ferrere, G., Alves-Costa-Silva, C., Ly, P., Wu, Q., Tian, A.-L., Derosa, L., Zitvogel, L., Kepp, O., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1789284 · Cited by 10

Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts

Kuiken, H. J., Dhakal, S., Selfors, L. M., Friend, C. M., Zhang, T., Callari, M., Schackmann, R. C. J., Gray, G. K., Crowdis, J. P., Bhang, H.-E. C., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02075-y · Cited by 9

Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics

Dwivedi, R., Pandey, R. K., Chandra, S., & Mehrotra, D. (2023) · Immunotherapy · doi:10.2217/imt-2022-0238 · Cited by 9

Type I interferons: One stone to concurrently kill two birds, viral infections and cancers

Kumar, A., Khani, A. T., & Swaminathan, S. (2021) · Current Research in Virological Science · doi:10.1016/j.crviro.2021.100014 · Cited by 9

Recombinant poliovirus for cancer immunotherapy

Jammal, M. P., Michelin, M. A., Nomelini, R. S., & Murta, E. F. C. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.07.19 · Cited by 9

ESCHERICHIA COLI STRAIN BL21: CLONING AND EXPRESSION OF AN OPTIMIZED INTERFERON ALPHA 2B (DE3)

Alrseetmiwe, D. S., Almayah, A. A., Nasser, A. A., Alnussairi, M. H., Alizadeh, H., & Mehrzi, F. A. (2020) · Journal of Life Science and Applied Research · doi:10.59807/jlsar.v1i2.15 · Cited by 8

Immune-epigenetic crosstalk in haematological malignancies

Wong, H., & Sugimura, R. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1233383 · Cited by 8

Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP

Rohilla, A., Singh, A. K., Koleske, B. N., Srikrishna, G., & Bishai, W. R. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02012-23 · Cited by 9

Self-generated double-stranded RNA for enhancing tumor immunotherapy and metastasis inhibition

Yu, Y., Tian, Y., Li, Y., Qin, X., Li, X., Hu, Q., Fu, C., Niu, B., Yang, C., Kong, L., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102173 · Cited by 8

The Toxoplasma Effector GRA4 Hijacks Host TBK1 to Oppositely Regulate Anti‐T. Gondii Immunity and Tumor Immunotherapy

Hu, Z., Zhang, Y., Xie, Y., Yang, J., Tang, H., Fan, B., Zeng, K., Han, Z., Lu, J., Jiang, H., et al. (2024) · Advanced Science · doi:10.1002/advs.202400952 · Cited by 8

NLRC3 Attenuates Antiviral Innate Immune Response by Targeting IRF7 in Grass Carp (Ctenopharyngodon idelus)

Zhang, L., Chen, H., Zhao, X., Chen, Y., Li, S., Xiao, T., & Xiong, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020840 · Cited by 8

The cold immunological landscape of ATM-deficient cancers

Sinha, S., Ng, V., Novaj, A., Zhu, Y., Yazaki, S., Pei, X., Derakhshan, F. N., Pareja, F. G., Setton, J. S., Naulin, F., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010548 · Cited by 8

Trem2 regulates microglial migratory responses via type I interferon signaling during photoreceptor degeneration

He, J., Zhou, W., & Li, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02261-5 · Cited by 8

PARP9-PARP13-PARP14 axis tunes colorectal cancer response to radiotherapy

Prokarenkaitė, R., Kuodyte, K., Gudoitytė, G., Budginaite, E., Naumovas, D., Strainienė, E., Velickevicius, K., Dulskas, A., Sileika, E., Venius, J., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03439-y · Cited by 8

Restoration of cGAS in cancer cells promotes antitumor immunity via transfer of cancer cell–generated cGAMP

Cryer, A. M., Dosta, P., Dion, M. Z., Soto, L. D. L. P., Amar‐Lewis, E., Carmona, G. G. D. L., Perez, A. A. E., Aguilar, D. F. R., Sanchez-Huerta, T. M., Ruiz, B. N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409556122 · Cited by 8

Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma

Ha, J., Wang, Y., Ma, Y., Wu, A., Dong, S., Jeong, S. D., Edwards, J. L., Chang, M., Chang, Y.-T., Wang, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70221-9 · Cited by 8

Detection of dendritic cell subsets in the tumor microenvironment by multiplex immunohistochemistry

van der Hoorn, I. A. E., Martynova, E., Subtil, B., Meek, J., Verrijp, K. N., Textor, J. C., Flórez‐Grau, G., Piet, B., van den Heuvel, M. M., de Vries, I. J. M., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202350616 · Cited by 8

Targeting Innate Immunity in Glioma Therapy

Gillard, A. G., Shin, D. H., Hampton, L. A., Lopez-Rivas, A. R., Parthasarathy, A., Fueyo-Margareto, J., & Gomez‐Manzano, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020947 · Cited by 8

Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription

Lv, Y., Sun, S., Zhang, J., Wang, C., Chen, C., Zhang, W., Zhao, J., Qi, Y., Zhang, W., Wang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216988 · Cited by 8

An immuno‐northern technique to measure the size of dsRNA byproducts in in vitro transcribed RNA

Clark, N. E., Schraut, M. R., Winters, R. A., Kearns, K., & Scanlon, T. C. (2024) · Electrophoresis · doi:10.1002/elps.202400036 · Cited by 8

N‐Dihydrogalactochitosan Drives Conventional and Alternative Activations of STING to Synergize Type I IFN and IL‐1β Productions for Antitumor Immunity.

Hoover, A. R., Liu, K., Furrer, C. L., Lam, S. S. K., Anderson, D. W., Zhou, Z., Yang, J., Wong, C. F., Medcalf, A. D., Sun, X., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202410079 · Cited by 8

Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b

Qin, A., Wu, D., Liao, J., Xie, S., Chen, H., Gao, Y., Cui, J., Su, X., Miyachi, N., Sato, T., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1455979 · Cited by 8

PFAS promotes colorectal cancer progression via regulating RIG-I-mediated innate immune signalling

Ding, C., Tao, G., Chen, G., Xie, Y., Yang, C., Qi, S., Hou, J., Jiang, X., Deng, X., & Liao, W. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2024.11.002 · Cited by 8

In Situ Delivery of Gasdermin E mRNA Promotes Antitumor Immunity via Creatine-Elicited Type I Interferon Signaling in Monocytes

Li, H., Lu, J., Tan, S., Jiang, T., He, X., Qiao, W., Hu, C., Dalangood, S., Lin, J., & Gui, J. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0834 · Cited by 8

A spatiotemporal cancer cell trajectory underlies glioblastoma heterogeneity

de Jong, G., Memi, F., Gracia, T., Lazareva, O., Gould, O., Solomou, G., Aivazidis, A., Dave, M., Zhang, Q., Jensen, M., et al. (2026) · Nature · doi:10.1101/2025.05.13.653495 · Cited by 10

Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?

Trono, P., Tocci, A., Musella, M., Sistigu, A., & Nisticò, P. (2021) · Biology · doi:10.3390/biology10090913 · Cited by 8

Distinctive gene expression patterns in pregnancy-associated breast cancer

Wang, D., Peng, H., Hu, Y., Piao, X., Gao, D., & Sha, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.850195 · Cited by 8

Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder

El‐Baky, N. A., Uversky, V. N., & Redwan, E. M. M. M. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.012 · Cited by 8

Microbiomics in Collusion with the Nervous System in Carcinogenesis: Diagnosis, Pathogenesis and Treatment

Hull, R., Lolas, G., Makrogkikas, S., Jensen, L. D., Syrigos, K. N., Evangelou, G., Padayachy, L. C., Egbor, C., Mehrotra, R., Makhafola, T. J., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9102129 · Cited by 8

Identification of Candidate Target Genes and Immune Cells in Oral Squamous Cell Carcinoma

Xie, P., Wu, S., Guo, L., Ren, J., Cai, K., Zhou, M., Liu, W., & Yang, S. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/5802110 · Cited by 8

2′-5′ oligoadenylate synthetase-like 1 (OASL1) deficiency suppresses central nervous system damage in a murine MOG-induced multiple sclerosis model

Choi, B. Y., Sim, C. K., Cho, Y. S., Sohn, M., Kim, Y.-J., Lee, M. S., & Suh, S. W. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.06.026 · Cited by 8

ORMDL3 restrains type I interferon signaling and anti-tumor immunity by promoting RIG-I degradationPreprint

Zeng, Q., Chen, Y., Zhang, S., Mao, Y., Wang, J., Wang, Z., Sheng, C., & Chen, S. (2024) · eLife · doi:10.7554/elife.101973.3 · Cited by 8

Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity

Hernandez-Franco, J. F., Jan, I. M., Elzey, B. D., & HogenEsch, H. (2024) · npj Vaccines · doi:10.1038/s41541-024-00943-8 · Cited by 7

Combination with oxaliplatin improves abscopal effect of oncolytic virotherapy through reorganization of intratumoral macrophages

Tomita, K., YAMASHITA, M., Ikegami, K., Shimizu, Y., Amino, N., & Nakao, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.007 · Cited by 7

Engineered vesicular cancer vaccines for immunosuppressive microenvironment reversion and in situ vaccine generation

Li, Y., Yu, Y., Xia, B., Zhao, S., Li, X., Hu, Q., Tian, Y., Wang, Y., Zhou, Y., Yang, C., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113658 · Cited by 7

Glioblastoma cells secrete ICAM1 via FASN signaling to promote glioma-associated macrophage infiltration

Zhang, W., Wang, J., Ji, J., Wang, P., Yuan, G., Fang, S., Liu, F., Jin, G., & Zhang, J. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111823 · Cited by 7

Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy

Enßle, S., Sax, A., May, P., Khawanky, N. E., Soliman, N., Perl, M., Enssle, J. C., Krey, K., Ruland, J., Pichlmair, A., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2504244 · Cited by 7

BAG2 Inhibits Cervical Cancer Progression by Modulating Type I Interferon Signaling through Stabilizing STING

Yao, S., Chen, S., Wang, A., Liang, Z., Liu, X., Gao, Y., & Cai, H. (2025) · Advanced Science · doi:10.1002/advs.202414637 · Cited by 9

Unlocking T‐Cell Plasticity in the Tumor Microenvironment: Implications for Cancer Progression and Therapeutic Strategies

Ding, X., Li, X., Chen, F., Wang, H., & Jiang, Y. (2025) · MedComm – Oncology · doi:10.1002/mog2.70023 · Cited by 7

Calreticulin Enhances Therapeutic Immune Responses of Dry Thermostat-Stressed Hepatocellular Carcinoma Cell Vaccine

Zhang, D., Fu, X., Zhou, C., Xing, X., Zheng, Y., Zhou, Y., Zheng, X., Chen, G., Zou, J., Zeng, Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c07598 · Cited by 7

Interferon-Based Therapeutics in Cancer Therapy: Past, Present, and Future

Vorona, K., Ryapolova, A., Sokolova, O., Karabelsky, A. V., Ivanov, R. A., Reshetnikov, V. V., & Minskaia, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311679 · Cited by 7

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45

Type I Interferons and Natural Killer Cell Regulation in Cancer

Müller, L., Aigner, P., & Stoiber, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00304 · Cited by 173

The added value of type I interferons to cytotoxic treatments of cancer

Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 20

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

Musella, M., Manic, G., Maria, R. D., Vitale, I., & Sistigu, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1314424 · Cited by 147